Michael R. Megna - Jul 15, 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF ACCOUNTING OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Jul 15, 2024
Transactions value $
-$74,954
Form type
4
Date filed
9/4/2024, 08:57 PM
Previous filing
Apr 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Award $7.51K +480 +2.2% $15.65 22.3K Jul 15, 2024 Direct F1
transaction KNSA Class A Ordinary Share Options Exercise +6.49K +29.16% 28.7K Sep 1, 2024 Direct F2
transaction KNSA Class A Ordinary Share Tax liability -$73.7K -2.76K -9.58% $26.74 26K Sep 1, 2024 Direct
transaction KNSA Class A Ordinary Share Options Exercise +775 +2.98% 26.8K Sep 2, 2024 Direct F2
transaction KNSA Class A Ordinary Share Tax liability -$8.8K -329 -1.23% $26.74 26.4K Sep 2, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Award $0 +9.45K $0.00 9.45K Sep 1, 2024 Class A Ordinary Share 9.45K Direct F2, F3
transaction KNSA Share Option Award $0 +18.9K $0.00 18.9K Sep 1, 2024 Class A Ordinary Share 18.9K $26.74 Direct F4
transaction KNSA Restricted Share Unit Options Exercise $0 -3.93K -33.33% $0.00 7.87K Sep 1, 2024 Class A Ordinary Share 3.93K Direct F2, F5
transaction KNSA Restricted Share Unit Options Exercise $0 -2.56K -25% $0.00 7.67K Sep 1, 2024 Class A Ordinary Share 2.56K Direct F2, F6
transaction KNSA Restricted Share Unit Options Exercise $0 -775 -50.03% $0.00 774 Sep 2, 2024 Class A Ordinary Share 775 Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2024 to July 15, 2024. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
F2 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F3 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.
F4 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024.
F5 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
F6 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.